Bio-Rad Q2 2025 revenue rises 2.1% to $651.6 million; raises full-year margin outlook
Bio-Rad reported second-quarter 2025 revenue of $651.6 million, up 2.1% from a year earlier. GAAP net income was $317.8 million, or $11.67 per diluted share, compared with a net loss a year earlier, mainly due to a change in the fair market value of its Sartorius AG investment. Non-GAAP net income fell to $71.0 million, or $2.61 per diluted share, from $88.3 million, or $3.11, and the company raised its non-GAAP operating margin outlook for 2025.
Key points
- Q2 2025 net sales were $651.6 million, up 2.1% from $638.5 million; currency-neutral sales rose 1.0%.
- GAAP net income was $317.8 million, or $11.67 per diluted share, versus a net loss of $(2,165.5) million, or $(76.26) per share, in Q2 2024.
- Non-GAAP net income was $71.0 million, or $2.61 per diluted share, versus $88.3 million, or $3.11, a year earlier.
- For full-year 2025, non-GAAP operating margin is now expected at approximately 12.0% to 13.0%, up from 10.0% to 12.0%; currency-neutral revenue growth is now expected at approximately 0% to 1.0%, versus a prior range of a 1.0% decline to 1.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.